Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 16/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168356 | 1.00 | F12 (0.45) | F12MAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL30633264 | 1.00 | F12 (0.45) | F12MAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL26018072 | 0.83 | F12 (0.51) | F12 | |
| SCHEMBL652744 | 0.81 | NR1H2 (0.48) | — | |
| SCHEMBL31740710 | 0.81 | BACE1 (0.45) | — | |
| SCHEMBL656294 | 0.81 | BACE1 (0.45) | — | |
| SCHEMBL13837003 | 0.81 | BACE1 (0.45) | — | |
| SCHEMBL7054647 | 0.81 | BACE1 (0.45) | — | |
| SCHEMBL21579620 | 0.81 | MAPT (0.47) | MAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20166269 | 0.81 | F12 (0.65) | F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541375-B1 | FACTOR XIIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-10875851-B2 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190352294-A1 | Factor XIIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3541375-A1 | FACTOR XIIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093695-A1 | FACTOR XIIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875851-B2 | Factor XIIa inhibitors | F11, F13B, SERPINC1 | F12 4/4885MAPT 4551/4885ALDH1A1 1906/4885 |
| US-20190352294-A1 | Factor XIIa Inhibitors | F11, F13B, SERPINC1 | F12 4/4885MAPT 4551/4885ALDH1A1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.